ProxofIM
Last funding round
Seed / pre-clinical — fundraising disclosed in academic publications
What they do in peptide space
ProxofIM is the spinout from Peter de Keizer's lab at the University of Groningen developing FOXO4-DRI as a clinical senolytic candidate. The Baar et al. 2017 Cell paper that introduced FOXO4-DRI established the mechanism — disruption of FOXO4-p53 binding triggers selective apoptosis in senescent cells — and ProxofIM is the corporate vehicle for moving the molecule from animal proof-of-concept toward human trials.
As of 2026, ProxofIM has not initiated registered human clinical trials. The company is in the pre-clinical optimization and Phase 1-enabling toxicology stage. We include it here because FOXO4-DRI is the most-discussed peptide-class senolytic in the longevity community despite the absence of human data — the mechanism is the cleanest among published senolytics, and ProxofIM is the only path the molecule has into legitimate clinical development.
Research-suppliers selling FOXO4-DRI peptide for self-experimentation are not affiliated with ProxofIM and are not what the company supplies.
Recent mentions
Coming soon — no editorial coverage or FDA alert mentioning ProxofIM in our index yet. Items will surface here as the news / FDA cron pipelines ingest them.